ACT-389949
ACT-389949 is a first-in-class, potent and selective and agonist of formyl peptide receptor type 2 (FPR2) /Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for the treatment of inflammatory disorders[1][2].
Product Specifications
CAS Number
1258417-54-7
UNSPSC
12352005
Hazard Statement
H302
Target
Formyl Peptide Receptor (FPR)
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/act-389949.html
Purity
99.96
Solubility
DMSO : 10 mg/mL (ultrasonic; adjust pH to 1 with HCl)
Smiles
O=C(C1=C(C2=CC=CC(C)=C2)OC(C)=N1)NC3=NN(CC4=NC(C(F)(F)C)=CO4)N=C3
Molecular Formula
C20H18F2N6O3
Molecular Weight
428.39
Precautions
H302
References & Citations
[1]Stalder AK, et al. Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949. Br J Clin Pharmacol. 2017 Mar;83 (3) :476-486.|[2]Lind S, et al. Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949. Biochem Pharmacol. 2019 Aug;166:163-173.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC682311-500 1x 500 µL
SOX10 (Melanoma Marker) (SOX10/2311R), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
